Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226832 | 0.77 | DYRK1A (0.47) | MAP3K7TAB1CCNCCDK8IP6K1 | |
| SCHEMBL12444889 | 0.74 | MAPT (0.39) | KDM4EMEN1MAPTKMT2ALMNA | |
| SCHEMBL2227349 | 0.74 | MAPT (0.39) | KDM4EMEN1MAPTKMT2ALMNA | |
| SCHEMBL2229144 | 0.71 | NTRK1 (0.36) | NTRK1LMNA | |
| SCHEMBL581279 | 0.71 | NPC1 (0.45) | CCNCCDK8LMNATRPM8 | |
| SCHEMBL5794035 | 0.64 | MAPT (0.56) | CCNCCDK8IP6K1IP6K2KDM4E | |
| SCHEMBL12501312 | 0.63 | MAPT (0.44) | CCNCCDK8METIP6K1IP6K2 | |
| SCHEMBL4089000 | 0.63 | IP6K1 (0.42) | CCNCCDK8METIP6K1IP6K2 | |
| SCHEMBL13719066 | 0.63 | IP6K1 (0.42) | CCNCCDK8METIP6K1IP6K2 | |
| SCHEMBL9639798 | 0.63 | NPC1 (0.43) | CCNCCDK8LMNATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | GOTO YASUHIRO | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183975-A1 | NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY | BRIX1, REL, CNKSR1 | MAP3K7 127/4885TAB1 161/4885CCNC 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.